@article {RosengartenP271, author = {Dror Rosengarten and Viktoria Rusanov and Oren Fruchter and Yael Raviv and Mordechai Kramer}, title = {Lung transplantation for silicosis, report of 17 patients}, volume = {44}, number = {Suppl 58}, elocation-id = {P271}, year = {2014}, publisher = {European Respiratory Society}, abstract = {Silicosis is a progressive, fibrotic lung disease resulting from inhalation of respirable crystalline silica. Silicosis is one of the most important occupational lung diseases worldwide and is associated with a high morbidity and mortality. Unfortunately, there is no medical treatment available for end-stage silicosis other than lung transplantation (LT). Nevertheless, Silicosis is a rare indication for LT which has been previously reported to result in poor outcome. Recently, a Silicosis outbreak reported in Israel, which has been attributed to exposure to artificial stone with high-silica-content. During the last 7 years, 60 patients with silicosis were referred for evaluation, among them, 17 patients underwent LT in the Rabin medical center. All patients were male and average age was 50.3 years. Average FEV1 was 31.6\% and average DLCO was 34.8\%. Average lung allocation score was 45.9. Single lung transplantation was performed in 82\% and 29\% were done with extracorporeal membrane oxygenation support. One year survival was 87.5\% and two years survival was 75\%, which is similar to the outcome of other transplantations in our center. Mean follow-up was 21.6{\textpm}18.3 months. Silicosis patients represent 5\% of all patients transplanted in our center. This rate is extremely high comparing to the rate reported in the United Network of Organ Sharing which was only 0.43\%. This tenfold increase in the rate of Silicosis patients transplanted in Israel represents the severity of the artificial stone silicosis outbreak.Conclusion:Artificial stone silicosis outbreak in Israel presents a challenge with increased rate of patients with severe Silicosis who required LT.LT offers an effective therapy for patients with end-stage silicosis.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/44/Suppl_58/P271}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }